CN107074951B - 拮抗性抗-ox40l抗体及其使用方法 - Google Patents

拮抗性抗-ox40l抗体及其使用方法 Download PDF

Info

Publication number
CN107074951B
CN107074951B CN201580052180.0A CN201580052180A CN107074951B CN 107074951 B CN107074951 B CN 107074951B CN 201580052180 A CN201580052180 A CN 201580052180A CN 107074951 B CN107074951 B CN 107074951B
Authority
CN
China
Prior art keywords
antibody
seq
cdr2
ser
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580052180.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107074951A (zh
Inventor
Y-J·刘
S·祖拉夫斯基
吴相坤
S·哈纳布奇
H·藤田
上野英树
P·布兰科
H·郑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Research Institute
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of CN107074951A publication Critical patent/CN107074951A/zh
Application granted granted Critical
Publication of CN107074951B publication Critical patent/CN107074951B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
CN201580052180.0A 2014-08-04 2015-08-03 拮抗性抗-ox40l抗体及其使用方法 Active CN107074951B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462032959P 2014-08-04 2014-08-04
US62/032959 2014-08-04
PCT/US2015/043408 WO2016022468A1 (en) 2014-08-04 2015-08-03 Antagonistic anti-ox40l antibodies and methods of their use

Publications (2)

Publication Number Publication Date
CN107074951A CN107074951A (zh) 2017-08-18
CN107074951B true CN107074951B (zh) 2021-08-03

Family

ID=55264394

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580052180.0A Active CN107074951B (zh) 2014-08-04 2015-08-03 拮抗性抗-ox40l抗体及其使用方法

Country Status (7)

Country Link
US (2) US10167339B2 (enExample)
EP (1) EP3194445A4 (enExample)
JP (1) JP6628787B2 (enExample)
CN (1) CN107074951B (enExample)
AU (1) AU2015301338C1 (enExample)
IL (1) IL250428B (enExample)
WO (1) WO2016022468A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
US20220372153A1 (en) * 2015-03-03 2022-11-24 Kymab Limited Synergistic combinations of ox40l antibodies for the treatment of gvhd
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018170764A1 (zh) * 2017-03-22 2018-09-27 深圳市博奥康生物科技有限公司 一种用于 RNAi 的载体及其应用
IL320945A (en) * 2017-10-18 2025-07-01 Alpine Immune Sciences Inc Immunomodulatory proteins, ligands for ICOs, and compositions and methods related thereto
CN108458964A (zh) * 2017-10-31 2018-08-28 天津协和华美医学诊断技术有限公司 一种抗体组合物及其在淋巴浆细胞性淋巴瘤微小残留检测中的应用
AU2020234533A1 (en) * 2019-03-12 2021-09-16 University Health Network TSG-6 antibodies and uses therefor
CN114980923A (zh) * 2019-12-06 2022-08-30 艾伯霖克斯公司 包含靶向TNFα和OX40L的免疫球蛋白单可变结构域的多肽
CA3176425A1 (en) * 2020-04-24 2021-10-28 Millennium Pharmaceuticals, Inc. Anti-cd19 antibodies and uses thereof
KR102705172B1 (ko) * 2020-12-09 2024-09-11 에이치케이이노엔 주식회사 항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도
US20240270859A1 (en) * 2020-12-09 2024-08-15 Hk Inno.N Corporation ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFa BISPECIFIC ANTIBODY, AND USES THEREOF
WO2023017252A1 (en) * 2021-08-10 2023-02-16 Kymab Limited Treatment of atopic dermatitis
WO2025031290A1 (zh) * 2023-08-04 2025-02-13 信达生物制药(苏州)有限公司 抗ox40l抗体以及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0978287A1 (en) * 1997-09-25 2000-02-09 Mitsui Chemicals, Inc. MEDICINAL COMPOSITION CONTAINING gp34 BINDING INHIBITOR AS THE ACTIVE INGREDIENT
WO2007133290A2 (en) * 2005-12-16 2007-11-22 Genentech, Inc. Anti-ox40l antibodies and methods using same
WO2011073180A1 (en) * 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291331B1 (en) * 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US20120020960A1 (en) 2010-07-26 2012-01-26 Baylor Research Institute Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0978287A1 (en) * 1997-09-25 2000-02-09 Mitsui Chemicals, Inc. MEDICINAL COMPOSITION CONTAINING gp34 BINDING INHIBITOR AS THE ACTIVE INGREDIENT
WO2007133290A2 (en) * 2005-12-16 2007-11-22 Genentech, Inc. Anti-ox40l antibodies and methods using same
WO2011073180A1 (en) * 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use

Also Published As

Publication number Publication date
IL250428B (en) 2021-03-25
AU2015301338A1 (en) 2017-02-23
WO2016022468A1 (en) 2016-02-11
AU2015301338C1 (en) 2021-07-22
CA2957314A1 (en) 2016-02-11
US20190092869A1 (en) 2019-03-28
EP3194445A1 (en) 2017-07-26
CN107074951A (zh) 2017-08-18
US10570208B2 (en) 2020-02-25
IL250428A0 (en) 2017-03-30
JP6628787B2 (ja) 2020-01-15
AU2015301338B2 (en) 2021-03-25
US20170349661A1 (en) 2017-12-07
EP3194445A4 (en) 2018-05-23
JP2017523984A (ja) 2017-08-24
US10167339B2 (en) 2019-01-01

Similar Documents

Publication Publication Date Title
CN107074951B (zh) 拮抗性抗-ox40l抗体及其使用方法
CN111954680B (zh) IL2Rβ/共同γ链抗体
CN112703013B (zh) Cd3抗原结合片段及其应用
US20230357396A1 (en) Monoclonal antibodies and methods for using same
CN113614108A (zh) G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
CN113840912A (zh) 包含识别分子的工程化免疫细胞
JP2022512917A (ja) Ｂ細胞成熟抗原に特異的なキメラ抗原受容体を使用する処置方法
JP2022532274A (ja) ヒトｔｒｂｖ９のベータ鎖領域に対するモノクローナル抗体
CN109414500A (zh) 治疗和诊断用pd-l1特异性单克隆抗体
US20230147657A1 (en) Chimeric antigen receptor specific for human cd45rc and uses thereof
JP2019512207A (ja) Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体
KR20220152227A (ko) Ｂｃｍａ-지시된 키메라 항원 수용체 ｔ 세포 조성물 및 이의 방법 및 용도
JP2022515820A (ja) ヒトｔｒｂｖ９に特異的に結合するモノクローナル抗体
US20240041929A1 (en) Chimeric antigen receptors specific for gprc5d and bcma
US20240182594A1 (en) Uses of antagonist, non-depleting ox40 antibodies
CN116178545B (zh) 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
JP2024527539A (ja) ＩＬ１３Ｒα２を標的としたユニバーサルＣＡＲ－Ｔ細胞及びその製造方法と使用
JP2024500511A (ja) 抗ｐｄ－ｌ１抗体及びその使用
CN115181180B (zh) 抗人程序性死亡配体-1（pd-l1）的抗体及其应用
CA2957314C (en) Antagonistic anti-ox40l antibodies and methods of their use
CN120712102A (zh) 对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
CN118974094A (zh) 一种抗原结合蛋白及其应用
EA042982B1 (ru) Моноклональные антитела против участка бета-цепи trbv9 человека

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant